南京帕尔斯生物科技有限公司

Bevacizumab (Synonyms: Anti-Human VEGF, Humanized Antibody)

采购热度:177 发布时间:2019/2/9

型号:HY-P9906

价格:电议 产地:中国大陆

简单介绍:Bevacizumab 是一种人源化的单克隆抗体,高亲和力且特异性地与所有 VEGF-A 结合。

详细介绍
Description

Bevacizumab, a humanized monoclonal antibody, specifically binds to all VEGF-A isoforms with high affinity.

IC50 & Target

VEGF[1]

In Vitro

Bevacizumab, a humanized monoclonal antibody, specifically binds to all VEGF-A isoforms with high affinity, and inhibits its interaction with VEGFR-1 and VEGFR-2[1]. Experimental analysis shows that the EC50 of Bevacizumab to bind VEGF analyzed by ELISA is 0.18 μg/mL. Binding kinetics assays show similar results that Bevacizumab inhibits the VEGF-induced proliferation of HUVEC with an IC50 value of 0.047±0.0081 μg/mL[2].

In Vivo

It is demonstrated that the subconjunctival administration of FD006, Bevacizumab and Dexamethasone can all significantly inhibit CoNV in NaOH cauterized rats compared with the control group (p < 0.01)[2]. The combination of NVP-LDE225 and Paclitaxel causes a long-lasting antitumor activity, with a tumor size of 1.64 cm3 at the end of the experiment, whereas Bevacizumab plus Paclitaxel-treated mice reaches the maximum allowed tumor size on day 84[3].

Clinical Trial
NCT Number Sponsor Condition Start Date Phase
NCT01578551 Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|National Cancer Institute (NCI) Carcinoma, Non-Small-Cell Lung|Lung Adenocarcinoma May 2012 Phase 2
NCT01269853 Northwell Health|Feinstein Institute for Medical Research Glioblastoma Multiforme|Anaplastic Astrocytoma October 2010 Phase 1|Phase 2
NCT00356122 Sanofi|Genentech, Inc. Non-Small Cell Lung Cancer July 2006 Phase 2
NCT00096967 Genentech, Inc. Breast Cancer|Colorectal Cancer|Metastases October 2002 Phase 3
NCT00393068 SCRI Development Innovations, LLC|Genentech, Inc. Esophageal Cancer February 2007 Phase 2

标签:Bevacizumab   

我要询价X

产品名称:

您的称呼:

您的电话:

您的单位:

您的要求:

  验证码:

提交